Interestingly, cGAS-STING pathway agonists show efficacy in preclinical PDAC tumors by targeting macrophages in the TME (Ager et al., 2021), suggesting that tumor cells or cells within the TME may respond to activation of this pathway. The gene discussed is STING1; the disease is neoplasm.